Abstract
Conjugation of poly(ethylene glycol) to proteins is a well known technique used to prolong half-life and reduce immunogenicity. In the case of interferon α, improving pharmacokinetics to reduce dosing frequency was the driving force in the development of two long-acting derivatives: PEG-Intron® by Schering-Plough and Pegasys® by Roche Pharmaceuticals. These conjugates, even though developed with a similar approach and for the same clinical use, present several differences that offer the possibility for an interesting and unique comparison. The basic PEGylation chemistry and characterization of the conjugates will be described together with an analysis of the pharmacokinetic/pharmacodynamic behaviors.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Cohen J. (1999) The scientific challenge of hepatitis C. Science 285: 26–30.
Liang TJ, Rehermann B, Seeff LB, and Hoofnagle JH. (2000) Pathogenesis, natural history, treatment, and prevention of hepatitis C. Annals of Internal Medicine 132: 296–305.
Simmonds P. (1999) Viral heterogeneity of the hepatitis C virus. Journal of Hepatology 31 (Suppl 1): 54–60.
Souvignet C, Lejeune O, and Trepo C. (2007) Interferon-based treatment of chronic hepatitis C. Biochimie 89: 894–898.
Palumbo E. (2007) PEG-interferon alpha-2b for acute hepatitis C: a review. Mini Rev Med Chem 7: 839–843.
Zeuzem S. (2008) Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol. 5: 610–622.
Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, and Reddy KR et al. (1998) Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 27: 1136–1143.
Blatt LM, Davis JM, Klein SB, and Taylor MW. (1996) The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. Journal of Interferon and Cytokine Research 16: 489–499.
Melian EB and Plosker GL. (2001) Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 61: 1661–1691.
Keeffe EB and Hollinger FB. (1997) Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. Hepatology 26: 101S–107S.
Heathcote EJ, James S, Mullen KD, Hauser SC, Rosenblate H, and Albert DG Jr (1999) Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group. Hepatology 30: 562–566.
Sjogren MH, Sjogren R, Holtzmuller K, Winston B, Butterfield B, and Drake S et al. (2005) Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. Digestive Diseases and Sciences 50: 727–732.
Thomas HC, Torok ME, Forton DM, Taylor-Robinson SD. (1999) Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J. Hepatol. 31 (Suppl. 1): 15229.
Dusheiko G, Main J, Thomas H, Reichard O, Lee C, and Dhillon A et al. (1996) Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J. Hepatol. 25: 591–598.
Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, and Yurdaydin C et al. (1995) Rivabirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123: 897–903.
Weiland O. (1999) Treatment of naive patients with chronic hepatitis. C. J. Hepatol. 31 (Suppl. 1): 168–173.
Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, and Ideo G et al. (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352: 1426–1432.
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, and Rustgi VK et al. (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine 339: 1485–1492.
Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, and Layden TJ. (1997) Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 26: 226–231.
Veronese FM, and Harris JM. (2002) Introduction and overview of peptide and protein pegylation. Advanced Drug Delivery Reviews 54: 453–456.
Veronese FM, and Pasut G. (2005) PEGylation, successful approach to drug delivery. Drug Discovery Today 10: 1451–1457.
Gilbert CW, and Park-Cho M-O. (1999) Interferon Polymer Conjugates US 5951974.
Zalipsky S, Seltzer R, and Menon-Rudolph S. (1992) Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins. Biotechnology and Applied Biochemistry 15: 100–114.
Miron T, and Wilchek M. (1993) A simplified method for the preparation of succinimidyl carbonate polyethylene glycol for coupling to proteins. Bioconjugate Chemistry 4: 568–569.
Pasut G, Guiotto A, and Veronese FM. (2004) Protein, peptide and non-peptide drug PEGylation for therapeutic application. Expert Opinion on Therapeutic Patents 14: 859–894.
Kozlowski A, Charles SA, and Harris JM. (2001) Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15: 419–429.
Kozlowski A, and Harris JM. (2001) Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J Control Release 72: 217–224.
Zalipsky S. (1995) Chemistry of polyethylene glycol conjugates with biologically active molecules. Advanced Drug Delivery Reviews 16: 157–182.
Roberts MJ, Bentley MD, and Harris JM. (2002) Chemistry for peptide and protein PEGylation. Advanced Drug Delivery Reviews 54: 459–476.
Wylie DC, Voloch M, Lee S, Liu YH, Cannon-Carlson S, and Cutler C et al. (2001) Carboxyalkylated histidine is a pH-dependent product of pegylation with SC-PEG. Pharmaceutical Research 18: 1354–1360.
Wang Y-S, Youngster S, Grace M, Bausch J, Bordens R, and Wyss DF. (2002) Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Advanced Drug Delivery Reviews 54: 547–570.
Grace M, Youngster S, Gitlin G, Sydor W, Xie L, and Westreich L et al. (2001) Structural and biologic characterization of pegylated recombinant IFN-alpha-2b. Journal of Interferon and Cytokine Research 21: 1103–1115.
Peginterferon alfa-2b Product Information. Kenilworth, NJ, USA: Schering Corporation.
Wang YS, Youngster S, Bausch J, Zhang R, McNemar C, and Wyss DF. (2000) Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 39: 10634–10640.
Nagabhushan TL, Reichert P, Walter MR, and Murgolo NJ. (2002) Type I interferon structures: Possible scaffolds for the interferon-alpha receptor complex. Canadian Journal of Chemistry 80: 1166–1173.
Chou CP, Yu CC, Lin WJ, Kuo BY, and Wang WC. (1999) Novel strategy for efficient screening and construction of host/vector systems to overproduce penicillin acylase in Escherichia coli. Biotechnology and Bioengineering 65: 219–226.
Monkarsh SP, Ma Y, Aglione A, Bailon P, Ciolek D, and DeBarbieri B et al. (1997) Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity. Analytical Biochemistry 247: 434–440.
Nieforth KA, Nadeau R, Patel IH, and Mould D. (1996) Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clinical Pharmacology and Therapeutics 59: 636–646.
Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, and Porter JE et al. (2001) Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chemistry 12: 195–202.
Reddy RK, Modi MW, and Pedder S. (2002) Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Advanced Drug Delivery Reviews 54: 571–586.
Peginterferon alfa-2a Complete Product Information. Nutley, NJ, USA: Roche Pharmaceuticals.
Algranati NE, Sy S, and Modi M. (1999) A branched methoxy 40 KDA polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon alpha-2a (peginterferon) and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 30:190A. Abstract 120.
Harris JM, Martin NE, and Modi M. (2001) Pegylation: A novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40: 539–551.
Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, and Gupta SK et al. (2000) Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clinical Pharmacology and Therapeutics 68: 556–567.
Wills RJ. (1990) Clinical Pharmacokinetics of interferons. Clin. Pharmacokinetic. 19: 390–399.
Lamb MW, and Martin NE. (2002) Weight-based versus fixed dosing of peginterferon (40 kDa) alfa-2a. Ann Pharmacothe 36: 933–935.
Modi M, Fulton JS, Buckman DK, Wright TL, and Moore D. (2000) Clearance of PEGylated (40 kDa) Interferon Alfa-2a (PEGASYS) is Primarily Hepatic. Hepatology 32: 371A.
Martin NE, and Modi MW. (2000) Characterization of pegylated (40KDA) interferon alfa-2a (PEGASYS) in the elderly. Hepatology 32: 348A. Abstract 755.
Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, and Maiocchi L et al. (2004) Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naïve patients with chronic hepatitis C: a randomized, controlled study. Antiviral Therapy 9: 491–497.
Formann E, Jessner W, Bennett L, and Ferenci P. (2003) Twice-weekly administration of pegin-terferon-a-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J. Vir. Hep. 10:271–276.
Sporea I, Danila M, Sirli R, Popescu A, Laza A, and Baditoiu L. (2006) Comparative study concerning the efficacy of Peg-IFN-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis. J. Gastrointestin. Liver Dis. 15: 125–130.
Yenice N, Mehtap O, Gümrah M, and Arican N. (2006) The efficacy of pegylated alpha 2a or 2b plus ribavarin in chronic hepatitis C patients. Turk. J. Gastroenterol. 17: 94–98.
Escudero A, Rodriguez F, Serra MA, Del Olmo JA, Montes F, and Rodrigo JM. (2008) Pegylated alpha-interferon-2a plus ribavarin compared with pegylated alpha-interferon-2b plus ribavarin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J. Gastroenterol. Hepatol. 23: 861–866.
Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A et al. (2009) Randomized trial comparing pegylated interferon α-2b versus pegylated interferon α-2a, both plus ribavarin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 49: 22–31.
Chou R, Carson S, and Chan BKS. (2008) Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials. J. Viral Hep. 15: 551–570.
Manns MP, McHutchinson J, Gordon S, Rustgi VK, Shiffman M, Reindollar R et al. (2001) Peginterferon alfa-2b plus ribavarin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358: 958–965.
Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R et al. (2001) Efficacy and safety of pegylated (40-KD) interferon alpha-2a compared with interferon alpha-2a in patients with in noncirrhotic patients with chronic hepatitis C. Hepatology 33: 433–438.
Zeuzem S, Feinman SV, Rasenack EJ, Heathcote EJ, La MJ, Gane E et al. (2000) Peginterferon alfa-2a in patients with chronic hepatitis C. New Eng. J. Med. 343: 1666–1672.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marino G, Goncales F et al. (2001) Pegylated interferon alfa-2a (Pegasys) in combination with ribavarin: efficacy and safety results from a phase III, randomized, actively controlled, multicenter study. Gastroenterology 120: A55.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347: 975–982.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Birkhäuser Verlag/Switzerland
About this chapter
Cite this chapter
Pasut, G. (2009). PEGylated α interferons: two different strategies to achieve increased efficacy. In: Veronese, F.M. (eds) PEGylated Protein Drugs: Basic Science and Clinical Applications. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8679-5_12
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8679-5_12
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-8678-8
Online ISBN: 978-3-7643-8679-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)